{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":406,"total_is_capped":false,"direct_labels_cover":2,"predictions_cover":406,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"0fcb7d059508","filters":{"venue":"The Oncologist"}},"results":[{"id":"W2109116356","doi":"10.1634/theoncologist.5-4-302","title":"SPIKES—A Six-Step Protocol for Delivering Bad News: Application to the Patient with Cancer","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"Patient-Provider Communication in Healthcare","field":"Health Professions","cited_by":3045,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Protocol (science); Medicine; Cancer; Medical information; Medical emergency; Medical physics; Medical education; Family medicine; Alternative medicine; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1853504159787481,"gpt":0.4751298314215793,"spread":0.2897794154428311,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0003225052,0.0001683521,0.0001952478,0.00002832801,0.001937669,0.00001558329,0.0008012139,0.0001159384,0.0003852964],"category_scores_gemma":[0.000113949,0.00008624288,0.00004238243,0.0002822904,0.0001168649,0.00006954405,0.000168267,0.0004547704,0.0003152636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006536408,"about_ca_system_score_gemma":0.0004992679,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01111897,"about_ca_topic_score_gemma":0.02553701,"domain_scores_codex":[0.9978448,0.000610892,0.0005329441,0.0002943903,0.0002397129,0.0004772323],"domain_scores_gemma":[0.9971414,0.0008250537,0.0003342939,0.001272824,0.0003125972,0.0001138243],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00390771,0.0003390663,0.02447893,0.0006481287,0.000049919,0.000001258179,0.03461218,0.008852124,0.000115534,0.002468075,0.1050032,0.8195239],"study_design_scores_gemma":[0.001074393,0.000627232,0.00496862,0.0002124448,0.00001712577,0.000001135655,0.004846278,0.001825662,0.00003097159,0.0001211196,0.9861271,0.0001479321],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.02467296,0.0001707019,0.004956186,0.1167175,0.0003573615,0.8307795,0.0001519135,0.0004089424,0.02178492],"genre_scores_gemma":[0.1195021,0.00001362151,0.002776545,0.008134561,0.0002495095,0.8684321,0.00001410491,0.00003329906,0.0008441701],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.8811239,"threshold_uncertainty_score":0.9993617,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3014319236","doi":"10.1634/theoncologist.2020-0213","title":"A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":719,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University; Juravinski Cancer Centre; University of Toronto; McMaster University; Windsor Regional Hospital; Impact","funders":"F. Hoffmann-La Roche","keywords":"Pandemic; Medicine; Outbreak; Disease; Public health; Cancer; Population; Intensive care medicine; Transmission (telecommunications); Coronavirus; Pneumonia; Infectious disease (medical specialty); Coronavirus disease 2019 (COVID-19); Environmental health; Virology; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.3677715450091028,"gpt":0.5553454666213564,"spread":0.1875739216122536,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008119101,0.0003531794,0.0008931069,0.00006463896,0.0002951703,0.00005115365,0.0007974349,0.000141009,0.00005736179],"category_scores_gemma":[0.0008318127,0.0001518449,0.0002165629,0.0005399673,0.000294231,0.00007846567,0.0005144656,0.0007125893,0.00002613893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002363141,"about_ca_system_score_gemma":0.002822472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001365225,"about_ca_topic_score_gemma":0.0005220914,"domain_scores_codex":[0.9973787,0.0004453668,0.000625492,0.0005078361,0.0007116645,0.0003309498],"domain_scores_gemma":[0.9972276,0.0006815934,0.0006194233,0.0007148582,0.0001868467,0.0005696691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003813247,0.003047144,0.00515273,0.02613962,0.002621077,0.0001445448,0.002794366,0.00008413098,9.702047e-7,0.004798951,0.005410988,0.9459922],"study_design_scores_gemma":[0.0009885723,0.0003283852,0.01991321,0.001237649,0.001572447,0.00001605183,0.000390512,0.00003173479,4.302585e-8,0.00001001818,0.975349,0.0001623729],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006721226,0.9224732,0.0008363714,0.05385589,0.001307166,0.0153786,0.003445407,0.0001314865,0.001899769],"genre_scores_gemma":[0.003437315,0.9854227,0.0003443308,0.008139662,0.0006312113,0.001226941,0.0002966212,0.00004561647,0.0004555509],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.969938,"threshold_uncertainty_score":0.6192056,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139939379","doi":"10.1634/theoncologist.2008-0232","title":"The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":692,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Docetaxel; Gemcitabine; Oncology; Internal medicine; Histology; Hazard ratio; Lung cancer; Proportional hazards model; Chemotherapy; Cisplatin; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1300508911499699,"gpt":0.5312090846097777,"spread":0.4011581934598078,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004384688,0.000319641,0.002834746,0.00009321517,0.0001969784,0.000006276103,0.0003723884,0.0000825932,0.00004308552],"category_scores_gemma":[0.0009386429,0.0001327197,0.0006444834,0.0004353654,0.0003995465,0.00001387896,0.0001270985,0.0002515511,0.000008685005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005451803,"about_ca_system_score_gemma":0.0006003399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007285988,"about_ca_topic_score_gemma":0.00003363924,"domain_scores_codex":[0.9979765,0.0002938058,0.0009788941,0.0002683737,0.0002426732,0.0002397723],"domain_scores_gemma":[0.9967241,0.001360483,0.0009245576,0.0007104091,0.0002133877,0.00006701805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001169376,0.000451582,0.000001191399,0.01496809,0.001451907,0.00001630974,0.0001336686,1.002546e-7,0.000001852276,0.0003201208,0.00931328,0.9732249],"study_design_scores_gemma":[0.00338651,0.00115491,0.000008244431,0.06865012,0.01647945,0.00005038065,0.0001401824,3.299835e-7,0.000002323922,0.00002637835,0.9099799,0.0001212836],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004824423,0.9918813,0.00002882233,0.002314094,0.0004243297,0.003050809,0.00003989056,0.00002452061,0.002187969],"genre_scores_gemma":[0.0005840316,0.9972361,0.0001053195,0.0003225997,0.0001993053,0.0003014162,0.00006199741,0.00002186735,0.001167357],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9731037,"threshold_uncertainty_score":0.5412151,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2160175915","doi":"10.1634/theoncologist.11-5-503","title":"Ewing's Sarcoma Family of Tumors: Current Management","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Sarcoma Diagnosis and Treatment","field":"Medicine","cited_by":518,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; CD99; Sarcoma; Ewing's sarcoma; Rhabdomyosarcoma; Radiology; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.120886286577146,"gpt":0.4047832080814213,"spread":0.2838969215042753,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003474137,0.000426433,0.001996098,0.0001479021,0.00007523037,0.00001657288,0.0003584593,0.0001319294,0.00004216264],"category_scores_gemma":[0.00002235858,0.0002184876,0.0007952611,0.0003092205,0.0002411787,0.00001395009,0.0002105844,0.0003269485,0.0001791861],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004783731,"about_ca_system_score_gemma":0.0001827309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001184288,"about_ca_topic_score_gemma":0.000007820899,"domain_scores_codex":[0.9979811,0.0001697248,0.0007892891,0.0003705432,0.0003696363,0.0003196797],"domain_scores_gemma":[0.9982067,0.0003052084,0.0005223167,0.0008485919,0.00004714218,0.00007007412],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001068218,0.00125426,0.0001194719,0.009425408,0.0003611675,0.0002817056,0.000007780977,2.42843e-7,4.308209e-8,0.0009545529,0.01806359,0.9695211],"study_design_scores_gemma":[0.0006431589,0.000255728,0.002390356,0.01391336,0.00426283,0.00007650813,0.00002388181,7.724877e-7,7.081005e-7,0.00007966314,0.9781788,0.0001742172],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0000501701,0.9678236,0.000006091842,0.0001283691,0.0003153641,0.001977403,0.00004988075,0.00005384635,0.02959525],"genre_scores_gemma":[0.0003004296,0.9976968,0.0002458045,0.00007642928,0.0002761823,0.0005510839,0.0001888615,0.00004558578,0.0006188046],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9693469,"threshold_uncertainty_score":0.8909666,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151507583","doi":"10.1634/theoncologist.12-4-426","title":"Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":418,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Sorafenib; Medicine; Clinical trial; Pharmacokinetics; Refractory (planetary science); Pharmacology; Oncology; Drug; Toxicity; Safety profile; Phases of clinical research; Internal medicine; Medical physics; Adverse effect; Hepatocellular carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.07306418962376841,"gpt":0.4061245175451803,"spread":0.3330603279214119,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002528225,0.0003788288,0.002687295,0.00008980659,0.00003630333,0.000004059964,0.0003572225,0.0002220103,0.00001672947],"category_scores_gemma":[0.0008430054,0.0002237392,0.0002925249,0.0001736305,0.0003485554,0.000005403218,0.0002122409,0.0002769179,0.000001033106],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004359872,"about_ca_system_score_gemma":0.0003932847,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001022978,"about_ca_topic_score_gemma":0.000007816653,"domain_scores_codex":[0.9969282,0.0009414047,0.00125477,0.0004084771,0.0002099864,0.0002571342],"domain_scores_gemma":[0.9968787,0.0003263841,0.002046304,0.0005431658,0.0001365758,0.00006879766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002108481,0.0008143817,0.00003217136,0.03626572,0.0001599065,0.000019974,0.000009222145,6.872654e-7,0.001041626,0.000005128835,0.0003713441,0.9591714],"study_design_scores_gemma":[0.006354828,0.01096288,0.0004801076,0.04862639,0.001515669,0.00003559519,0.00001116645,0.000001256548,0.004239493,0.000004528715,0.9271909,0.0005771985],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01443642,0.982094,0.0000513755,0.00001695019,0.0001241218,0.002377074,0.0003499078,0.000005730272,0.0005444643],"genre_scores_gemma":[0.0152949,0.983953,0.0001913688,0.00005513,0.0000918709,0.00006934455,0.0002504617,0.00003608641,0.00005783149],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9585941,"threshold_uncertainty_score":0.912382,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157270051","doi":"10.1634/theoncologist.11-2-165","title":"Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":371,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Foothills Medical Centre; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Glioma; Multidisciplinary approach; MEDLINE; Intensive care medicine; Oncology; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.08917163167619094,"gpt":0.3812659846141838,"spread":0.2920943529379928,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007573431,0.0004506944,0.001330217,0.0001971061,0.0002587828,0.0000252975,0.0004794382,0.0001645599,0.00007367177],"category_scores_gemma":[0.00001002723,0.0001797938,0.0005457077,0.0005145826,0.0002507253,0.00001973883,0.0002686624,0.0002546567,0.0001878737],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002873059,"about_ca_system_score_gemma":0.00007147613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004479822,"about_ca_topic_score_gemma":0.00001198425,"domain_scores_codex":[0.997937,0.0002760022,0.0005887661,0.0004221918,0.0003522297,0.0004238615],"domain_scores_gemma":[0.9978241,0.0003244956,0.0005172518,0.001231043,0.00003026928,0.00007285023],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007116341,0.002297543,0.0000201667,0.005984424,0.001236772,0.00290419,0.0001004612,0.00001397078,0.00000139625,0.02168858,0.003631333,0.96205],"study_design_scores_gemma":[0.0008205089,0.0009997879,0.000343632,0.01396084,0.005123995,0.0002692456,0.0003038927,0.00002171012,0.00004768786,0.0001991931,0.9776278,0.0002817484],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002128406,0.9827387,0.000004261905,0.001531534,0.0002557411,0.003101598,0.00007730762,0.00006016552,0.01010224],"genre_scores_gemma":[0.005450848,0.9923226,0.0001552048,0.00009685286,0.0002070028,0.0009283297,0.0002319345,0.00005812715,0.0005490742],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9739964,"threshold_uncertainty_score":0.733178,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144648936","doi":"10.1634/theoncologist.12-5-610","title":"Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency; Vrije Universiteit Amsterdam; Institut Claudius Regaud; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cetuximab; Colorectal cancer; Toxicity; Grading (engineering); Quality of life (healthcare); Gefitinib; Cancer; Oncology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.2509656558099983,"gpt":0.5050140510855577,"spread":0.2540483952755594,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005214107,0.0006931298,0.00323603,0.0003271105,0.0001877309,0.00010485,0.001084568,0.001173388,0.0009907439],"category_scores_gemma":[0.002596084,0.0004567489,0.0007404728,0.0009537217,0.0008560323,0.00009606191,0.0004476983,0.003440897,0.0005204474],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004655972,"about_ca_system_score_gemma":0.00116641,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004411816,"about_ca_topic_score_gemma":0.0005070983,"domain_scores_codex":[0.9920124,0.002213276,0.002396948,0.0009924154,0.001084926,0.001299964],"domain_scores_gemma":[0.9941779,0.003310145,0.0007292143,0.001174266,0.0001516111,0.000456864],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001534373,0.0008835969,0.0007536177,0.007352759,0.0004276781,0.002483862,0.0001965167,5.363864e-7,2.443877e-7,0.0001816145,0.01448052,0.9730856],"study_design_scores_gemma":[0.0009746379,0.001585707,0.000557997,0.01326998,0.0004968955,0.0002127985,0.0002312427,0.00001830358,0.000001145689,0.00008209625,0.9820623,0.0005068809],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008544303,0.9749979,0.00001573513,0.0008178535,0.001686643,0.004815883,0.000159568,0.0002571468,0.01639481],"genre_scores_gemma":[0.001170985,0.9925544,0.0003061966,0.0006061313,0.001697763,0.0003198606,0.0002365285,0.0001561717,0.002951924],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9725788,"threshold_uncertainty_score":0.9999225,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133116306","doi":"10.1634/theoncologist.9-5-561","title":"Management of Bleeding in Patients with Advanced Cancer","year":2004,"lang":"en","type":"review","venue":"The Oncologist","topic":"Spinal Hematomas and Complications","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cancer; Intensive care medicine; MEDLINE; General surgery; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.05221294789071874,"gpt":0.4006685865191679,"spread":0.3484556386284491,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007157432,0.0001301454,0.0006595138,0.00005344169,0.00002748403,0.000002612222,0.0001540728,0.00005299066,0.00002992371],"category_scores_gemma":[0.000003209752,0.00006473749,0.00007779905,0.0003127974,0.00008290224,0.00001151656,0.00005102269,0.0001486175,0.000008855353],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003988548,"about_ca_system_score_gemma":0.0001477223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004603874,"about_ca_topic_score_gemma":0.00001483762,"domain_scores_codex":[0.99931,0.00001378633,0.0002688635,0.0001488245,0.0001389351,0.0001196037],"domain_scores_gemma":[0.999393,0.00002422515,0.0002264015,0.0002900876,0.00004227426,0.00002404045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004713106,0.000256994,0.0004077995,0.01407563,0.0001306763,0.0000101225,0.00001296603,0.000007287727,1.35787e-8,0.002388305,0.00002333944,0.9826397],"study_design_scores_gemma":[0.002190354,0.0009640778,0.02303539,0.1301497,0.002042957,0.000009855644,0.00008760824,9.89009e-7,5.794558e-7,0.0001197354,0.8411798,0.0002189196],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004244583,0.9910386,0.00001109896,0.00009413525,0.00004670756,0.00142643,0.000008993342,0.0000147948,0.006934744],"genre_scores_gemma":[0.001996418,0.9966058,0.0005662699,0.00002039648,0.00001707435,0.0004655817,0.00002057877,0.00001608776,0.000291752],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9824208,"threshold_uncertainty_score":0.2639918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165229942","doi":"10.1634/theoncologist.2010-0197","title":"Effect of Exercise Training on Peak Oxygen Consumption in Patients with Cancer: A Meta-Analysis","year":2011,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cancer survivorship and care","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Meta-analysis; Confidence interval; VO2 max; Randomized controlled trial; Physical therapy; Adverse effect; Pooled variance; Internal medicine; Heart rate","retraction":null,"screen_n_in":null,"score":{"opus":0.1610448786288721,"gpt":0.3910357770130435,"spread":0.2299908983841715,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001007747,0.0003675096,0.004712143,0.0002895547,0.00003495266,0.000007095639,0.0002316531,0.0002769826,0.0005951841],"category_scores_gemma":[0.00004752231,0.0001618818,0.001460784,0.0006518836,0.000186669,0.00001800796,0.00003862508,0.0005217519,0.0000171464],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003064864,"about_ca_system_score_gemma":0.0002009771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002718468,"about_ca_topic_score_gemma":0.00425191,"domain_scores_codex":[0.9980373,0.0005995381,0.0004922713,0.00035205,0.0003007556,0.0002181057],"domain_scores_gemma":[0.9982312,0.0004552919,0.0005777389,0.0006102997,0.00006219816,0.00006325052],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001025272,0.0001521172,0.00174805,0.01037871,0.04207208,0.00001144029,0.0008709575,0.000005758854,1.438505e-8,0.00001542013,0.00009170178,0.9436285],"study_design_scores_gemma":[0.001214037,0.002332774,0.002988068,0.003738001,0.8250265,0.000001674032,0.00004339768,0.00000120575,9.939793e-7,0.000001706103,0.1643877,0.0002640116],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001991346,0.9947417,0.000001555829,0.00002967124,0.0001146624,0.001886298,0.0001523932,0.00002099216,0.001061329],"genre_scores_gemma":[0.01369528,0.9846827,0.000006083564,0.00004119056,0.00003246836,0.000946332,0.000170319,0.00003379771,0.0003918728],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9433644,"threshold_uncertainty_score":0.6601348,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2151979638","doi":"10.1634/theoncologist.10-5-345","title":"HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":275,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital Notre-Dame","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Rash; Medicine; Dermatology; Acne; EGFR inhibitors; Adverse effect; Etiology; Epidermal growth factor receptor; Pathology; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.06765387642643766,"gpt":0.3690442441056063,"spread":0.3013903676791686,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001742594,0.0008477163,0.002094452,0.0002196557,0.0008607135,0.00021942,0.0008134564,0.0007210657,0.0001195286],"category_scores_gemma":[0.0003768025,0.0004593384,0.0007415533,0.0007671631,0.0007497151,0.0001178279,0.0008779916,0.001006151,0.0001337487],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.02464092,"about_ca_system_score_gemma":0.001710903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007082001,"about_ca_topic_score_gemma":0.00202077,"domain_scores_codex":[0.9952219,0.0006560895,0.00118668,0.001000334,0.0009616412,0.0009733287],"domain_scores_gemma":[0.9954547,0.00199912,0.0007255999,0.001382029,0.0001723335,0.0002662195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008916452,0.0002956603,0.0001664224,0.004670236,0.00283228,0.00008559924,0.0003188115,0.000002887964,4.574006e-7,0.0009735762,0.1546518,0.8359131],"study_design_scores_gemma":[0.008315518,0.0001924832,0.0006919724,0.004983954,0.004231035,0.0000406461,0.001298453,0.00008448099,0.000002181252,0.0004009621,0.9792988,0.000459528],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004299894,0.9668371,0.00003665835,0.01599333,0.001892872,0.01082411,0.0003028295,0.0002890661,0.003394047],"genre_scores_gemma":[0.0003203413,0.9710605,0.0008466061,0.001818704,0.002833218,0.002669672,0.0009517524,0.0001606165,0.01933862],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8354536,"threshold_uncertainty_score":0.9997858,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2117590220","doi":"10.1634/theoncologist.11-6-590","title":"Cancer in 15- to 29-Year-Olds by Primary Site","year":2006,"lang":"en","type":"review","venue":"The Oncologist","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":268,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Medicine; Ethnic group; Race (biology); Cancer survival; Demography; Quarter (Canadian coin); Incidence (geometry); Cancer; Cancer incidence; Gerontology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0429315510139662,"gpt":0.3956065011842133,"spread":0.3526749501702471,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008378666,0.0004438845,0.001987531,0.0002187791,0.00007253229,0.00003614266,0.0006463529,0.0005462872,0.0004566688],"category_scores_gemma":[0.0002614541,0.0002534666,0.0002825998,0.0009006607,0.0003166406,0.00002976273,0.0004367995,0.001066932,0.001205071],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008618591,"about_ca_system_score_gemma":0.004033627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003141962,"about_ca_topic_score_gemma":0.0008236799,"domain_scores_codex":[0.9970993,0.0003143442,0.000677251,0.0005654998,0.0006277452,0.0007158607],"domain_scores_gemma":[0.9978964,0.0007716692,0.0002117442,0.0008354043,0.00007833407,0.000206493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007611753,0.000128806,0.00008674953,0.003978653,0.00007628042,0.000213797,0.00003046109,0.000003295143,0.000006482178,0.00001523311,0.4990898,0.4962943],"study_design_scores_gemma":[0.00098772,0.0002558128,0.0002017715,0.004792381,0.0004427816,0.00007773814,0.000008624914,0.000006379353,0.000001482985,0.000006932456,0.9929646,0.0002537911],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006075608,0.9580952,0.00002362436,0.001627331,0.000234618,0.002339305,0.0003379068,0.00007116902,0.0372101],"genre_scores_gemma":[0.00001742565,0.9563975,0.0001775686,0.001335371,0.0007158205,0.0007387652,0.000329778,0.00009460095,0.04019312],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4960406,"threshold_uncertainty_score":0.9999918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2102718441","doi":"10.1634/theoncologist.2010-0307","title":"Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer","year":2011,"lang":"en","type":"article","venue":"The Oncologist","topic":"Glycosylation and Glycoproteins Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":253,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"University of Texas MD Anderson Cancer Center; Merck KGaA","keywords":"Medicine; Keyhole limpet hemocyanin; Cyclophosphamide; Adjuvant; Metastatic breast cancer; Internal medicine; Breast cancer; Population; Seroconversion; Immunology; Cancer; Gastroenterology; Oncology; Chemotherapy; Antibody","retraction":null,"screen_n_in":null,"score":{"opus":0.1108185418277803,"gpt":0.4328358542687114,"spread":0.3220173124409311,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001144137,0.0001443906,0.0002751382,0.00002139869,0.0001458976,0.00001435419,0.0005448858,0.000122572,0.0002265484],"category_scores_gemma":[0.0003923679,0.00007731902,0.0002696466,0.0001042854,0.0002597166,0.000004420971,0.0002145224,0.0001752344,0.00001007283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002386518,"about_ca_system_score_gemma":0.0001910288,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003391838,"about_ca_topic_score_gemma":0.0004620966,"domain_scores_codex":[0.9984433,0.0003243744,0.0005029083,0.0002806219,0.0001761138,0.0002726617],"domain_scores_gemma":[0.9988534,0.0001015749,0.0002735399,0.0004991998,0.0001953555,0.00007691796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4657739,0.01556044,0.00449765,0.0001733911,0.001413185,0.0000122167,0.0008138465,0.00009589807,0.3295066,0.0009314104,0.0532832,0.1279383],"study_design_scores_gemma":[0.4725222,0.01569602,0.009094536,0.00007196281,0.0006370337,0.00005936312,0.0008275042,0.002791893,0.3209096,0.000530109,0.1761417,0.0007181329],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938134,0.0001573217,0.0006889416,0.001729873,0.000469501,0.002014256,0.0002314187,0.00001012841,0.0008851867],"genre_scores_gemma":[0.9966688,0.0001298282,0.0003934989,0.0004675223,0.0004047235,0.0001764609,0.00003089956,0.00001893948,0.001709369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1272202,"threshold_uncertainty_score":0.3152978,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2474699717","doi":"10.1634/theoncologist.2016-0097","title":"Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)","year":2016,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; AstraZeneca; Pfizer","keywords":"Medicine; Palbociclib; Fulvestrant; Neutropenia; Placebo; Metastatic breast cancer; Internal medicine; Adverse effect; Febrile neutropenia; Oncology; Common Terminology Criteria for Adverse Events; Breast cancer; Cancer; Chemotherapy; Estrogen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.009780463777112593,"gpt":0.2961600474988715,"spread":0.2863795837217589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001637433,0.0005385301,0.002782019,0.000368302,0.0001399998,0.00003040523,0.0002783897,0.00007535746,0.0002983999],"category_scores_gemma":[0.0001984554,0.0002488737,0.0001624124,0.001277117,0.0009329398,0.0003297587,0.00005179965,0.0003778697,0.000007260314],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002084187,"about_ca_system_score_gemma":0.0003142217,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003258374,"about_ca_topic_score_gemma":0.01761851,"domain_scores_codex":[0.9954724,0.001562737,0.001007919,0.0007344231,0.0005777818,0.0006447301],"domain_scores_gemma":[0.995349,0.002872747,0.0007854419,0.0005480141,0.0002682832,0.0001764918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.922018,0.00410069,0.01005934,0.00001070193,0.005557809,0.0001590918,0.008550045,0.0008919238,0.002119895,0.00001275703,0.000001942788,0.04651782],"study_design_scores_gemma":[0.8678102,0.00320548,0.1114971,0.0003666551,0.002477429,0.00001269116,0.01316927,0.0007200459,0.0002259359,0.0001513913,0.00001107496,0.0003526542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9820181,0.0004904721,0.005325763,0.003071016,0.00004696229,0.008514379,0.0003606701,0.00007728184,0.00009541795],"genre_scores_gemma":[0.9925421,0.0004480006,0.001485648,0.0002197664,0.00004035548,0.004999788,0.00003646436,0.00005300854,0.0001748175],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1014378,"threshold_uncertainty_score":0.9999964,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2121508408","doi":"10.1634/theoncologist.2015-0026","title":"Financial Distress and Its Associations With Physical and Emotional Symptoms and Quality of Life Among Advanced Cancer Patients","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":237,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Institute of Nursing Research; National Cancer Institute; National Institutes of Health","keywords":"Interquartile range; Medicine; Psychosocial; Distress; Quality of life (healthcare); Confidence interval; Hospital Anxiety and Depression Scale; Anxiety; Internal medicine; Psychiatry; Clinical psychology","retraction":null,"screen_n_in":null,"score":{"opus":0.05155118971980753,"gpt":0.2882291464719882,"spread":0.2366779567521806,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002764764,0.0001024024,0.000366473,0.00002685775,0.000101214,0.00002791992,0.00007681957,0.00006179766,0.000007575497],"category_scores_gemma":[0.0004842987,0.00008175497,0.00002279944,0.00006303403,0.0003145052,0.0002232201,0.00006282893,0.00009521795,0.000002397969],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001011874,"about_ca_system_score_gemma":0.00006736648,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007540226,"about_ca_topic_score_gemma":0.0007553134,"domain_scores_codex":[0.9993058,0.00001979358,0.0002888038,0.000201242,0.00003656963,0.0001477852],"domain_scores_gemma":[0.9992067,0.0001049157,0.0004365904,0.00008775909,0.00007123705,0.00009275907],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00008411275,0.0000929548,0.9297197,0.00001643435,0.00002630361,1.007526e-7,0.000544694,0.00006324245,0.000001639107,0.06763284,0.0001363905,0.001681554],"study_design_scores_gemma":[0.001336215,0.0002199521,0.9914308,0.00001346422,0.000008058944,1.215925e-7,0.00004324639,0.0002698753,0.00000662764,0.006100731,0.0004510072,0.0001198745],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951385,0.001169367,0.00003117333,0.0004415049,0.0001078537,0.0001779637,0.0007719739,0.000008424576,0.002153245],"genre_scores_gemma":[0.9993355,0.0002021385,0.00002690766,0.0001360399,0.00009926427,0.00002556415,0.00001248413,0.000007714741,0.0001543793],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06171109,"threshold_uncertainty_score":0.3333871,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135108459","doi":"10.1634/theoncologist.5-6-471","title":"The Initial Results in Muscle-Invading Bladder Cancer of RTOG 95-06: Phase I/II Trial of Transurethral Surgery Plus Radiation Therapy with Concurrent Cisplatin and 5-Fluorouracil Followed by Selective Bladder Preservation or Cystectomy Depending on the Initial Response","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":218,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; University of Alberta","funders":"National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Medicine; Bladder cancer; Urology; Cystoscopy; Radiation therapy; Concomitant; Cisplatin; Cystectomy; Surgery; Urinary bladder; Chemotherapy; Urinary system; Cancer; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.09270750294284641,"gpt":0.3860997258673921,"spread":0.2933922229245457,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002090967,0.0002707472,0.0005496689,0.00007880662,0.0003704892,0.00003044885,0.000159937,0.0001507161,0.0001254395],"category_scores_gemma":[0.0005385877,0.0001243256,0.0001092997,0.0004529897,0.000426798,0.000149428,0.00001685153,0.0003850046,8.376826e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003040785,"about_ca_system_score_gemma":0.0009583822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00130853,"about_ca_topic_score_gemma":0.001086915,"domain_scores_codex":[0.9969277,0.001200069,0.0007053377,0.000323747,0.0005160163,0.0003270976],"domain_scores_gemma":[0.9945543,0.004547786,0.0004089757,0.0002994656,0.0001260082,0.0000634727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8586194,0.001187547,0.0003717382,0.00002276881,0.0005669504,0.0000332544,0.00832435,0.0001349707,0.003679633,0.00002723228,0.003459684,0.1235725],"study_design_scores_gemma":[0.7631294,0.07062022,0.03623755,0.001168837,0.001425845,0.00007934706,0.003280089,0.002739446,0.1036884,0.0001736789,0.01644246,0.001014841],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922709,0.0007539646,0.00001872539,0.003015359,0.0001856775,0.002609527,0.000267479,0.00002512167,0.0008531878],"genre_scores_gemma":[0.9974539,0.001301102,0.00000848375,0.0002330744,0.0002162435,0.0004767139,0.00005090937,0.00002946772,0.0002300802],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1225577,"threshold_uncertainty_score":0.5069852,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166336441","doi":"10.1634/theoncologist.8-4-381","title":"Venous Thrombosis in Cancer Patients: Insights from the FRONTLINE Survey","year":2003,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Venous thromboembolism; Cancer; Thrombosis; Malignancy; Venous thrombosis; Intensive care medicine; MEDLINE; Low molecular weight heparin; Surgery; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.05359443108603156,"gpt":0.3261288330397681,"spread":0.2725344019537365,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004943188,0.0001640001,0.0004508358,0.00003070354,0.0001742065,0.00002675403,0.0002529579,0.00008050812,0.0003910491],"category_scores_gemma":[0.0004323196,0.00008090321,0.00006589562,0.0002602641,0.0001876977,0.00004055845,0.00007720661,0.000243532,0.00008938554],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003077872,"about_ca_system_score_gemma":0.0001198748,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03415025,"about_ca_topic_score_gemma":0.04834519,"domain_scores_codex":[0.9985057,0.0004291232,0.0002920342,0.00025751,0.000246372,0.0002692526],"domain_scores_gemma":[0.9987313,0.0005267079,0.0001176217,0.0004874977,0.00008317259,0.0000536651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001518141,0.007870054,0.8623499,0.00002307363,0.0004355666,0.00002374677,0.004144402,0.0001856039,0.0001240325,0.002683535,0.1161285,0.005879727],"study_design_scores_gemma":[0.001297369,0.0004246586,0.9494284,0.00005075445,0.0001321095,2.415401e-7,0.0003506943,0.0000184121,0.0001005881,0.0004856651,0.0476066,0.0001044548],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844777,0.001743735,0.00001312019,0.003186906,0.000640097,0.0008789964,0.00004408233,0.00003375995,0.008981593],"genre_scores_gemma":[0.992758,0.001392157,0.00005256608,0.005229467,0.0001304015,0.0001622763,0.00006508626,0.00002102778,0.0001889995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08707851,"threshold_uncertainty_score":0.9722815,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2397623993","doi":"10.1634/theoncologist.2016-0006","title":"Referral Criteria for Outpatient Palliative Cancer Care: A Systematic Review","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Referral; Palliative care; Medicine; Family medicine; Cancer; Nursing; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.4229028458163722,"gpt":0.5719189273617419,"spread":0.1490160815453697,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006747163,0.0004682128,0.004934334,0.00006518659,0.00007744069,0.00001032904,0.0004181002,0.0002741149,0.000122329],"category_scores_gemma":[0.002078353,0.0001966808,0.0009917355,0.0001894012,0.0002357495,0.00002630208,0.00009603033,0.0002565582,0.00007006662],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001020328,"about_ca_system_score_gemma":0.0007049153,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007569896,"about_ca_topic_score_gemma":0.00004114773,"domain_scores_codex":[0.997233,0.0005338058,0.001235962,0.0003716965,0.0002996507,0.0003258524],"domain_scores_gemma":[0.9958516,0.001433561,0.001334041,0.0007660845,0.0005212816,0.000093373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00003066579,0.00003729346,0.000003483531,0.9316694,0.000555747,0.00000644952,0.0005037322,6.111189e-9,1.456774e-7,0.0001333086,0.012389,0.05467076],"study_design_scores_gemma":[0.0002162499,0.0003083342,4.916351e-7,0.4975914,0.005475936,0.000003065558,0.00009935058,1.488027e-7,9.275907e-7,0.00001128108,0.4961706,0.0001222261],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[5.253484e-7,0.9872998,0.0000482273,0.0006526184,0.0006043556,0.008722604,0.0006805745,0.00004019087,0.001951127],"genre_scores_gemma":[0.000003839305,0.9900745,0.0002704259,0.0007383151,0.0004091401,0.005972205,0.000176499,0.0000553316,0.002299732],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4837815,"threshold_uncertainty_score":0.8020411,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168507982","doi":"10.1634/theoncologist.2014-0372","title":"Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":198,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; McMaster University; Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Federación Española de Enfermedades Raras; Cancer Research UK; Breast Cancer Research Foundation","keywords":"Breast cancer; Expression (computer science); Cancer; Cancer research; Computational biology; Biology; Oncology; Medicine; Genetics; Computer science","retraction":null,"screen_n_in":null,"score":{"opus":0.02440197533705295,"gpt":0.3159511142045415,"spread":0.2915491388674886,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001687523,0.0001389831,0.0001392908,0.00001139237,0.0001343419,0.00001638599,0.0001824766,0.00007869602,0.00003199153],"category_scores_gemma":[0.00008957897,0.00008621373,0.00004008308,0.00007229255,0.0002528806,0.00000409083,0.0001675281,0.00007475627,0.00006136834],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009747352,"about_ca_system_score_gemma":0.0001275549,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005557543,"about_ca_topic_score_gemma":0.0002563315,"domain_scores_codex":[0.9992368,0.0001028167,0.0001146809,0.0002409117,0.0001090503,0.0001957557],"domain_scores_gemma":[0.9994782,0.00004278392,0.00009528753,0.0002173545,0.0001056289,0.00006074618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002341612,0.0003134524,0.06013636,0.00001402027,0.0003007692,0.000004518456,0.001182821,0.0001012237,0.1195584,0.0009323061,0.7918496,0.02326492],"study_design_scores_gemma":[0.006217277,0.001738303,0.08416206,0.0001571868,0.0002412371,0.00008664557,0.008166548,0.00001987431,0.3558813,0.0006046952,0.5415782,0.001146661],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9651399,0.01856994,0.0002080573,0.008977433,0.0007912595,0.0003007755,0.0005366989,0.00005972077,0.005416169],"genre_scores_gemma":[0.9973756,0.0005665745,0.0006199311,0.0004648573,0.0001887514,0.0001206589,0.0001026936,0.00001750605,0.0005433972],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2502714,"threshold_uncertainty_score":0.3515694,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2142170680","doi":"10.1634/theoncologist.2011-0237","title":"Sorafenib for Patients with Advanced Angiosarcoma: A Phase II Trial from the French Sarcoma Group (GSF/GETO)","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Angiosarcoma; Medicine; Sorafenib; Sarcoma; Soft tissue sarcoma; Clinical endpoint; Internal medicine; Surgery; Toxicity; Oncology; Chemotherapy; Clinical trial; Pathology; Hepatocellular carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.02287312741647877,"gpt":0.2980100239155186,"spread":0.2751368964990398,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005646895,0.0002807323,0.000480765,0.00003164792,0.0005967571,0.00002943094,0.0003702299,0.0001036668,0.0001041344],"category_scores_gemma":[0.0002763613,0.000126265,0.0003313889,0.0002059522,0.0003290772,0.0001376975,0.0001408782,0.0002678619,0.00002553957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001075145,"about_ca_system_score_gemma":0.00008473209,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002281022,"about_ca_topic_score_gemma":0.000122495,"domain_scores_codex":[0.9982258,0.0001510037,0.0003353398,0.0002927571,0.0003884421,0.0006066605],"domain_scores_gemma":[0.9982448,0.0005301278,0.0002118813,0.0007377879,0.0001030464,0.0001723785],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2176005,0.06934869,0.1556215,0.0001521643,0.002856519,0.000120347,0.009987747,0.00001219374,0.003745353,0.005735107,0.1329541,0.4018658],"study_design_scores_gemma":[0.4133177,0.03521223,0.1940479,0.0001723591,0.00165926,0.0000353569,0.0008777402,0.0001325848,0.0004458637,0.001064588,0.3523201,0.0007143124],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900924,0.001555065,0.0006054003,0.003231157,0.000597955,0.003059003,0.0001369747,0.00009354351,0.0006284835],"genre_scores_gemma":[0.9938969,0.00001782519,0.002273283,0.001146978,0.001470869,0.0003948352,0.0003605752,0.00004538592,0.0003933415],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4011515,"threshold_uncertainty_score":0.5148938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135678986","doi":"10.1634/theoncologist.10-6-412","title":"AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy","year":2005,"lang":"en","type":"review","venue":"The Oncologist","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":172,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lymphoma; Sarcoma; Disease; Immunology; Cancer; Malignancy; Population; Oncology; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.08541992104712179,"gpt":0.3694902386719141,"spread":0.2840703176247923,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001131703,0.0004285165,0.001847916,0.0001275519,0.0001193644,0.00001512982,0.0006019018,0.0004977665,0.00009260204],"category_scores_gemma":[0.0001493335,0.0002029855,0.0006098538,0.0006433088,0.0004030919,0.00005783222,0.00005855728,0.00129298,0.00002739843],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004934264,"about_ca_system_score_gemma":0.0006161162,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003255343,"about_ca_topic_score_gemma":0.0001432093,"domain_scores_codex":[0.9974092,0.0006414431,0.0007414871,0.0003693878,0.0003994303,0.0004390343],"domain_scores_gemma":[0.9980378,0.0004660477,0.0007794012,0.0006130534,0.00006470809,0.00003895625],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009783969,0.000251668,0.00001612888,0.0007604958,0.000320318,0.00002816984,0.00197562,0.000002761847,0.000001898134,0.0007080865,0.0007301354,0.9951069],"study_design_scores_gemma":[0.002072957,0.002006351,0.0003028211,0.004786115,0.0007270323,0.00003074915,0.004589783,0.000003379568,0.00000256364,0.0001795032,0.9850209,0.000277825],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001117773,0.9758087,4.386666e-7,0.00297701,0.00020825,0.001408211,0.00003154255,0.00004539214,0.01840263],"genre_scores_gemma":[0.01647771,0.9823115,0.00001615233,0.0003988304,0.0001945583,0.0001692913,0.00004509463,0.00004804086,0.0003387881],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9948291,"threshold_uncertainty_score":0.827751,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2486839133","doi":"10.1634/theoncologist.2016-0186","title":"Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":163,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"Agència de Gestió d'Ajuts Universitaris i de Recerca; National Cancer Institute; U.S. Food and Drug Administration; National Institutes of Health","keywords":"Hedgehog signaling pathway; Vismodegib; Basal cell carcinoma; Discontinuation; Medicine; Dysgeusia; Adverse effect; Quality of life (healthcare); Hedgehog; Smoothened; Internal medicine; Oncology; Signal transduction; Biology; Basal cell; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.01326332922236419,"gpt":0.2538260286317334,"spread":0.2405626994093692,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002388922,0.0003231323,0.0006420708,0.0000623726,0.00005912303,0.000002272951,0.0002358967,0.0002302845,0.000003890871],"category_scores_gemma":[0.00001775985,0.0001826586,0.000100318,0.0001396849,0.0001846882,0.000004436036,0.0002856654,0.000119293,0.000007463417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000755789,"about_ca_system_score_gemma":0.00009092309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000003086998,"about_ca_topic_score_gemma":0.000006390554,"domain_scores_codex":[0.9985073,0.0002077934,0.0004884982,0.0004168665,0.0001464011,0.0002331907],"domain_scores_gemma":[0.99898,0.00002737175,0.0005057852,0.0003811981,0.00006696444,0.00003869191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000530902,0.0007994816,0.01353425,0.01375332,0.0005423033,0.00003110361,0.0001873047,0.000007842125,0.00269205,0.00003984928,0.00005302616,0.9678286],"study_design_scores_gemma":[0.01059178,0.004334833,0.1109987,0.01953337,0.0009256647,0.000005783846,0.0001646759,0.000001747343,0.004192306,0.00001705332,0.8474541,0.001779972],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.4796363,0.5173507,0.00004889326,0.00001574445,0.000251639,0.002013811,0.000197719,0.00001152071,0.0004737161],"genre_scores_gemma":[0.1652496,0.8333201,0.00006315994,0.00001695472,0.00004618702,0.0001505505,0.0005053811,0.00004712679,0.0006008707],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9660486,"threshold_uncertainty_score":0.7448603,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2719623628","doi":"10.1634/theoncologist.2017-0072","title":"Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":158,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"Cancer Research UK; AstraZeneca; American Society of Clinical Oncology; Pfizer","keywords":"Palbociclib; Fulvestrant; Medicine; Goserelin; Anastrozole; Internal medicine; Oncology; Breast cancer; Adverse effect; Neutropenia; Placebo; Letrozole; Gynecology; Cancer; Metastatic breast cancer; Chemotherapy; Tamoxifen","retraction":null,"screen_n_in":null,"score":{"opus":0.02206593019534308,"gpt":0.3371386426214998,"spread":0.3150727124261567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002995182,0.0003219509,0.0004976324,0.00005313869,0.0003886244,0.00006266612,0.0002871,0.0000608854,0.00002835875],"category_scores_gemma":[0.00003776151,0.0001531973,0.00001638395,0.0001068331,0.000988199,0.000180777,0.00007025772,0.0003768025,0.000002523155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003448621,"about_ca_system_score_gemma":0.0002447782,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00018743,"about_ca_topic_score_gemma":0.0007256797,"domain_scores_codex":[0.9982732,0.00006838008,0.0002704791,0.0004886982,0.0003599646,0.0005393102],"domain_scores_gemma":[0.9984123,0.0001112568,0.0003822666,0.0008507885,0.00009553602,0.0001478903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2487009,0.0007418265,0.0403353,0.00007491041,0.0001767207,0.0003994837,0.002023934,0.00009134987,0.007364981,0.0001081168,0.0000224937,0.69996],"study_design_scores_gemma":[0.03727097,0.01476186,0.9398801,0.0009472894,0.00003616068,0.0002935355,0.0007724527,0.00002247919,0.002495643,0.0001502883,0.003081044,0.0002881226],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813605,0.0003978201,0.000005208969,0.01516129,0.00006601561,0.001648497,0.00005621009,0.00008880354,0.001215668],"genre_scores_gemma":[0.9970024,0.0005228762,0.0007079193,0.0004145923,0.0001241536,0.0007225432,0.000007627903,0.00004899911,0.0004488642],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8995448,"threshold_uncertainty_score":0.6247206,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2094948739","doi":"10.1634/theoncologist.2014-0229","title":"Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety","year":2015,"lang":"en","type":"review","venue":"The Oncologist","topic":"Nausea and vomiting management","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Aprepitant; Medicine; Chemotherapy-induced nausea and vomiting; Antiemetic; Adverse effect; Vomiting; Nausea; Oncology; Pharmacology; Internal medicine; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1153224472111678,"gpt":0.4187728673947717,"spread":0.3034504201836039,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00247901,0.0002948515,0.002241002,0.00006427668,0.00006486623,0.00001260664,0.0001990483,0.0001531285,0.0001128966],"category_scores_gemma":[0.001044891,0.0001554268,0.0001823468,0.0002071648,0.0003845173,0.00001867842,0.000363907,0.0002940215,0.00004320753],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001317814,"about_ca_system_score_gemma":0.0002463695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001455251,"about_ca_topic_score_gemma":0.00000179694,"domain_scores_codex":[0.9981313,0.0003053028,0.0007349494,0.0003554109,0.0002622867,0.0002107366],"domain_scores_gemma":[0.9980189,0.0005228089,0.0005356667,0.0006887043,0.0001042391,0.0001296428],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006881313,0.00007885767,0.000003543438,0.1425049,0.0002169461,0.00003092826,0.00003048434,8.112478e-9,1.339445e-7,0.0006457652,0.01924575,0.8371739],"study_design_scores_gemma":[0.0007793343,0.000495668,0.0000400077,0.09583086,0.003490797,0.0001158244,0.00002079407,5.145062e-7,1.112718e-7,0.00004629202,0.8990443,0.0001355382],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000006883603,0.9708206,0.000003749958,0.0008237216,0.00007200613,0.002399919,0.00003080425,0.00003835539,0.02580396],"genre_scores_gemma":[0.00001429543,0.9968644,0.000219753,0.0002718806,0.0001421537,0.00005685884,0.0000392375,0.00003002306,0.002361435],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8797985,"threshold_uncertainty_score":0.6338121,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2112983735","doi":"10.1634/theoncologist.6-2-147","title":"Early Lung Cancer Action Project: A Summary of the Findings on Baseline Screening","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"National Cancer Institute; Eastman Kodak","keywords":"Medicine; Baseline (sea); Lung cancer; Action (physics); Oncology; Internal medicine; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1264352953099308,"gpt":0.4413769561260123,"spread":0.3149416608160815,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004882839,0.0003205229,0.001115422,0.0000876963,0.0001605928,0.00001754113,0.0002713891,0.0002218418,0.0001067524],"category_scores_gemma":[0.0001085364,0.0001342964,0.0005451024,0.0005153852,0.0001624046,0.00002573744,0.00009489272,0.0005393667,0.000008466348],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001270321,"about_ca_system_score_gemma":0.0007735755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003354205,"about_ca_topic_score_gemma":0.0003920341,"domain_scores_codex":[0.9983917,0.000248287,0.0004389926,0.0003265878,0.0003431275,0.0002512347],"domain_scores_gemma":[0.9983257,0.0005052403,0.0004518197,0.0006088109,0.00006616118,0.00004228317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001182333,0.000291155,0.001521879,0.00517035,0.0006411644,0.0000219512,0.00007628324,0.000004000625,4.124033e-7,0.00003834516,0.04028973,0.9518265],"study_design_scores_gemma":[0.0006453263,0.0004077952,0.001475241,0.03182466,0.004437067,0.00003202096,0.00002277299,0.00001307387,0.000008634223,0.000002180825,0.9609987,0.0001325068],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00031226,0.99061,0.000005979157,0.001570284,0.0004869981,0.002851741,0.0001046062,0.00003849445,0.004019641],"genre_scores_gemma":[0.0003455089,0.9927746,0.00004402366,0.0003261166,0.0005889867,0.0009715551,0.00004715742,0.00004356837,0.004858463],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.951694,"threshold_uncertainty_score":0.5476447,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157027442","doi":"10.1634/theoncologist.12-9-1114","title":"Temozolomide for the Treatment of Metastatic Melanoma: A Systematic Review","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"Ontario Ministry of Health and Long-Term Care; Cancer Care Ontario","keywords":"Temozolomide; Medicine; Dacarbazine; Oncology; Internal medicine; Clinical trial; Melanoma; Thalidomide; Meta-analysis; Randomized controlled trial; Phases of clinical research; Adverse effect; Chemotherapy; Cancer research; Multiple myeloma","retraction":null,"screen_n_in":null,"score":{"opus":0.1528189824131178,"gpt":0.4248340182340609,"spread":0.2720150358209431,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001458235,0.0003820866,0.003691832,0.00009485526,0.0001293733,0.00001340642,0.0003111357,0.00009422924,0.0000729344],"category_scores_gemma":[0.0004283526,0.0001375549,0.001297622,0.0002941977,0.0001827189,0.000007557427,0.00003527306,0.0001336135,0.00009008648],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005809466,"about_ca_system_score_gemma":0.0001970226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004728267,"about_ca_topic_score_gemma":0.00005830745,"domain_scores_codex":[0.9977192,0.0003027014,0.00121823,0.0002557557,0.0002513292,0.0002527919],"domain_scores_gemma":[0.9947534,0.003016022,0.001020695,0.001067762,0.00008316978,0.00005896937],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002867809,0.0002223131,2.937404e-8,0.6955155,0.001605122,0.0000508447,0.0000288314,1.296589e-7,5.420551e-8,0.0001844752,0.002258906,0.3001051],"study_design_scores_gemma":[0.0003469609,0.001553447,1.152366e-7,0.1461417,0.04493613,0.0008476875,0.00008412012,0.00000569092,6.622994e-7,0.000009376055,0.8059739,0.0001002332],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[2.124634e-7,0.976463,0.0003344928,0.0005284388,0.0003456708,0.02047384,0.00003485297,0.00004451739,0.001775022],"genre_scores_gemma":[0.000003603897,0.9836568,0.0001985231,0.0004481174,0.0001368404,0.003457444,0.00003584369,0.00004040381,0.01202247],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.803715,"threshold_uncertainty_score":0.5609328,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2119824367","doi":"10.1634/theoncologist.6-suppl_4-12","title":"Answering Patients' Needs: Oral Alternatives to Intravenous Therapy","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Medicine; Capecitabine; Quality of life (healthcare); Medical prescription; Patient education; Tegafur; Intensive care medicine; Bolus (digestion); Oncology; Internal medicine; Colorectal cancer; Chemotherapy; Cancer; Pharmacology; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.1077921430445384,"gpt":0.4047876122001642,"spread":0.2969954691556257,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001655705,0.0003893657,0.001506821,0.000125531,0.000177058,0.00003084443,0.0002518842,0.00009321274,0.0001274998],"category_scores_gemma":[0.00007581295,0.0001860953,0.0003108644,0.0004511627,0.0001530907,0.00002066105,0.0001333038,0.0002808912,0.0001013674],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007179033,"about_ca_system_score_gemma":0.0001856634,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003125914,"about_ca_topic_score_gemma":0.0001187385,"domain_scores_codex":[0.9986892,0.0001030201,0.0003528103,0.0002753694,0.000215591,0.0003639884],"domain_scores_gemma":[0.9991243,0.0001661985,0.0001770061,0.0003489001,0.00007878034,0.0001047671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001288944,0.000325563,0.0001569539,0.0003513545,0.0005463534,0.0000588548,0.0005749897,3.45469e-7,5.759336e-8,0.00002314594,0.00129508,0.9965384],"study_design_scores_gemma":[0.0006913574,0.003006102,0.0006959862,0.001441936,0.0004945867,0.00003559858,0.0001477348,2.05318e-7,5.668422e-7,0.00001409951,0.9932835,0.0001883503],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001069562,0.9795709,0.000007241729,0.0003410535,0.0004765551,0.00207252,0.00003366201,0.00006808389,0.01636048],"genre_scores_gemma":[0.0006235283,0.9952789,0.00007378035,0.000472899,0.0003865907,0.0004441837,0.0000413123,0.00004290931,0.00263588],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.99635,"threshold_uncertainty_score":0.7588745,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2613439971","doi":"10.1634/theoncologist.2016-0415","title":"Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study","year":2017,"lang":"en","type":"review","venue":"The Oncologist","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Medicine; Internal medicine; Retrospective cohort study; Oncology; Germline mutation; Cancer; Family history; Gastroenterology; Mutation; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.2001530791259961,"gpt":0.4553380343336708,"spread":0.2551849552076747,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001656958,0.000492183,0.004251034,0.0000839389,0.0002680821,0.0000585394,0.0004445342,0.0003697868,0.00002168306],"category_scores_gemma":[0.00172793,0.0002863795,0.0008105391,0.00009872433,0.000799141,0.00004307849,0.0005384643,0.001017308,0.00001740447],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003993873,"about_ca_system_score_gemma":0.0003480015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003892421,"about_ca_topic_score_gemma":0.0003694791,"domain_scores_codex":[0.9968914,0.0006063944,0.001163547,0.0006050038,0.0003814144,0.0003522893],"domain_scores_gemma":[0.9964367,0.0005876708,0.001532772,0.001063115,0.0002563827,0.0001234174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000267542,0.001908729,0.7405941,0.002037527,0.003916485,0.0002835883,0.0005255997,1.766438e-9,1.292054e-7,0.00002782375,0.001445323,0.2489931],"study_design_scores_gemma":[0.002784407,0.001640298,0.8509332,0.001949214,0.007138746,0.00002389206,0.0001761209,0.000001076989,2.642431e-8,0.000004877728,0.1351163,0.0002318068],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.03335736,0.9589632,5.574302e-7,0.0001769419,0.001109209,0.002778662,0.0002244355,0.0000495576,0.003340111],"genre_scores_gemma":[0.2179115,0.7802305,0.000008919825,0.00004448007,0.0005698621,0.00007497235,0.00006039245,0.00004670443,0.00105269],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.2487613,"threshold_uncertainty_score":0.9999588,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2547499110","doi":"10.1634/theoncologist.2015-0084","title":"Targeting the KRAS Pathway in Non-Small Cell Lung Cancer","year":2016,"lang":"en","type":"review","venue":"The Oncologist","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":135,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Lung cancer; Medicine; Targeted therapy; Cancer research; Adenocarcinoma; Cancer; Oncogene; Oncology; Internal medicine; Colorectal cancer; Cell cycle","retraction":null,"screen_n_in":null,"score":{"opus":0.02495525306450048,"gpt":0.3139234364054693,"spread":0.2889681833409689,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009122072,0.0003138318,0.0005149034,0.00003638742,0.0001734964,0.00003451251,0.0006336508,0.0003706293,0.00006900728],"category_scores_gemma":[0.00009110357,0.0001410949,0.0002706814,0.0001366315,0.0001713518,0.000001665451,0.0002771262,0.000306996,0.0000295535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001191219,"about_ca_system_score_gemma":0.0005197517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008414759,"about_ca_topic_score_gemma":0.0001019139,"domain_scores_codex":[0.9983352,0.000391381,0.0004304011,0.0003852438,0.0001105563,0.0003471785],"domain_scores_gemma":[0.9989116,0.0001025553,0.0003899516,0.0005079623,0.00004370174,0.00004425105],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00002359825,0.00006977569,0.00003171826,0.002806282,0.000110915,0.00002491801,0.00007013734,0.00009980767,0.005044932,0.000103572,0.005783,0.9858313],"study_design_scores_gemma":[0.0002032256,0.00003521585,0.000003686627,0.001739251,0.00006916202,0.000005495317,0.00001758213,0.00002249986,0.001154476,0.00001535678,0.9964932,0.0002409147],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001518262,0.9957799,0.0003836833,0.0002074099,0.0002512121,0.001120281,0.00004958285,0.00001132097,0.002044724],"genre_scores_gemma":[0.001377348,0.9946387,0.00006451947,0.0002043855,0.0008539869,0.0005641209,0.00008016896,0.00004380172,0.002172908],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9907101,"threshold_uncertainty_score":0.5753683,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3109542415","doi":"10.1002/onco.13596","title":"Update on Guidelines for the Management of Cancer-Associated Thrombosis","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Clinical Practice; Disease management; Intensive care medicine; MEDLINE; Disease; Cancer; Best practice; Evidence-based practice; Alternative medicine; Family medicine; Pathology; Health management system; Political science; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.2789887118213781,"gpt":0.492051057123135,"spread":0.2130623453017569,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008424228,0.0004067333,0.002375684,0.00005322774,0.0002134834,0.00002584132,0.0007285977,0.0001705924,0.0001462905],"category_scores_gemma":[0.0001642918,0.0001794713,0.0008155142,0.0003750182,0.0001957201,0.00001277728,0.000293926,0.0002786236,0.000064726],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003986923,"about_ca_system_score_gemma":0.0001887652,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002692592,"about_ca_topic_score_gemma":0.0001023298,"domain_scores_codex":[0.9979236,0.0001114936,0.0008660372,0.0003968666,0.000372462,0.0003295953],"domain_scores_gemma":[0.9976475,0.0005112845,0.0008244934,0.0007474095,0.0002079957,0.00006130372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001904247,0.0002994743,0.000001024387,0.007650331,0.004483622,0.000008060162,0.00002595788,0.00001199996,6.920966e-8,0.003805158,0.2419197,0.7417756],"study_design_scores_gemma":[0.0005221573,0.0005157163,0.0001623626,0.01002577,0.01830523,9.174875e-7,0.0001255837,0.00002432956,0.000001487707,0.00008948702,0.9700562,0.0001706987],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000003441176,0.963318,0.00003588913,0.02701651,0.0006905168,0.005358018,0.0002029654,0.00006829199,0.003306336],"genre_scores_gemma":[0.00003422142,0.9916304,0.0003013904,0.004130567,0.0004245133,0.002398902,0.0001098657,0.00006620293,0.0009039033],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7416049,"threshold_uncertainty_score":0.7318627,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2130760214","doi":"10.1634/theoncologist.2009-0122","title":"The Assessment and Management of Delirium in Cancer Patients","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Intensive Care Unit Cognitive Disorders","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"National Institute of Nursing Research; National Cancer Institute; U.S. Food and Drug Administration; National Institutes of Health","keywords":"Delirium; Cancer; Medicine; Intensive care medicine; Psychology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.06672662386925798,"gpt":0.438528488223297,"spread":0.3718018643540391,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003517685,0.0002036187,0.0007639904,0.00006538295,0.0000675703,0.000009876481,0.000179876,0.0001049076,0.00001254962],"category_scores_gemma":[0.0002827045,0.00009401487,0.0001396975,0.0001952606,0.0003316335,0.00000995835,0.0001145347,0.000355257,0.000004023813],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004297322,"about_ca_system_score_gemma":0.0002049324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008269037,"about_ca_topic_score_gemma":0.00009914542,"domain_scores_codex":[0.9988193,0.0001866977,0.0004001627,0.0001896796,0.0002048296,0.0001993114],"domain_scores_gemma":[0.9977273,0.0003031958,0.0002763017,0.0002570415,0.00140811,0.00002801796],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001995679,0.0001115,0.0002572867,0.002550087,0.0001774246,0.00001857455,0.00001956085,1.250137e-7,2.418523e-8,0.0003415539,0.004906967,0.9915969],"study_design_scores_gemma":[0.0006948775,0.0003395304,0.01670746,0.01096481,0.001262192,0.000004123207,0.0006897797,0.000001835985,1.592497e-7,0.00005200894,0.9691665,0.0001166794],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007880342,0.9779359,0.000003787406,0.001820684,0.0001980838,0.001956127,0.00002174352,0.000007690222,0.01797715],"genre_scores_gemma":[0.0002318528,0.9961401,0.00004047311,0.002729165,0.00002786449,0.0002370887,0.00004271789,0.00001642676,0.0005343078],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9914802,"threshold_uncertainty_score":0.3833815,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2907407844","doi":"10.1634/theoncologist.2018-0838","title":"An Open-Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM-080301 in Subjects with Advanced Hepatocellular Carcinoma","year":2018,"lang":"en","type":"article","venue":"The Oncologist","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":122,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Weill Cornell Medical College; AstraZeneca; Genentech; Eli Lilly and Company; Agios Pharmaceuticals; Exelixis","keywords":"Medicine; Hepatocellular carcinoma; Cohort; Pharmacokinetics; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Toxicity; Gastroenterology; Phases of clinical research; Small interfering RNA; RNA","retraction":null,"screen_n_in":null,"score":{"opus":0.06688128871368598,"gpt":0.3491842452595836,"spread":0.2823029565458976,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007496428,0.000324944,0.0005859021,0.0001068641,0.000349383,0.00004018401,0.0003284612,0.00006345593,0.00002832472],"category_scores_gemma":[0.00004210244,0.0001722342,0.00002119459,0.0004031268,0.0004224489,0.0002134247,0.0002392281,0.0002195115,0.000002858895],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001380647,"about_ca_system_score_gemma":0.0001629046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008967217,"about_ca_topic_score_gemma":0.0005608173,"domain_scores_codex":[0.9980378,0.0003796128,0.0003711181,0.0005349538,0.0003257481,0.0003508227],"domain_scores_gemma":[0.9985447,0.0001671765,0.0002345004,0.0006807623,0.0001872206,0.0001856342],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.09249515,0.02461972,0.629335,0.00005030107,0.0001318307,0.0008310854,0.003732887,0.000004561045,0.1274365,0.000002102185,0.00001469017,0.1213462],"study_design_scores_gemma":[0.07414326,0.3416941,0.3750373,0.0002274291,0.001131834,0.0001996943,0.00116165,0.03586861,0.1700238,0.000003302312,0.0001282667,0.0003808177],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904872,0.0001640032,0.0001840344,0.000498727,0.00005955328,0.008426675,0.00003427762,0.00003602694,0.000109537],"genre_scores_gemma":[0.9983654,0.0000656095,0.0008818599,0.0001236316,0.00007289739,0.0003591849,0.00005374025,0.00004127965,0.00003641517],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3170743,"threshold_uncertainty_score":0.7023508,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2107651401","doi":"10.1634/theoncologist.12-10-1156","title":"Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor–Positive Operable Breast Cancer","year":2007,"lang":"en","type":"article","venue":"The Oncologist","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; University of Alberta","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Cardiorespiratory fitness; Cardiology; Cardiac function curve; Oncology; Brain natriuretic peptide; Tamoxifen; Cancer; Endocrinology; Heart failure","retraction":null,"screen_n_in":null,"score":{"opus":0.01321203356464362,"gpt":0.2841265179975229,"spread":0.2709144844328793,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001254049,0.0001657957,0.000469047,0.00004547927,0.0001224656,0.00001311061,0.00009100384,0.0001009086,0.00008871272],"category_scores_gemma":[0.00005074804,0.0001087904,0.0001558972,0.0001648612,0.000274126,0.00006933964,0.00003729416,0.0002040793,0.000002297647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003241897,"about_ca_system_score_gemma":0.0001126987,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001125571,"about_ca_topic_score_gemma":0.00005795523,"domain_scores_codex":[0.9988261,0.00008383938,0.000242259,0.0002638355,0.0002320693,0.0003519162],"domain_scores_gemma":[0.9990548,0.0001544663,0.0001102599,0.0003432912,0.0002386221,0.00009859134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02609552,0.0005498536,0.008910538,0.0001421631,0.003449307,0.00003203654,0.004066563,0.00002391912,0.785472,0.00006122753,0.002118203,0.1690787],"study_design_scores_gemma":[0.009437905,0.003032228,0.2428396,0.00008641605,0.0003378424,0.0001606326,0.001453423,0.00003256453,0.729678,0.0001355409,0.01254596,0.0002597882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897605,0.005975638,0.0001587506,0.001091839,0.00008117162,0.001678378,0.0003067513,0.00003128562,0.0009157184],"genre_scores_gemma":[0.9917723,0.005649636,0.0005873115,0.0004075634,0.0003846913,0.0004654639,0.00003214588,0.00002931905,0.0006715661],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2339291,"threshold_uncertainty_score":0.4436343,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127779058","doi":"10.1634/theoncologist.2014-0381","title":"Is There a Role for Oral or Intravenous Ascorbate (Vitamin C) in Treating Patients With Cancer? A Systematic Review","year":2015,"lang":"en","type":"review","venue":"The Oncologist","topic":"Vitamin C and Antioxidants Research","field":"Nursing","cited_by":113,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Center for Complementary and Integrative Health; National Center for Complementary and Alternative Medicine; National Institutes of Health","keywords":"Medicine; Observational study; Randomized controlled trial; Placebo; Internal medicine; Toxicity; Chemotherapy; Meta-analysis; Vitamin; Cancer; Oncology; Pathology; Alternative medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1009348817684576,"gpt":0.4190439661201262,"spread":0.3181090843516685,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001970977,0.0005532509,0.003742556,0.0001249912,0.0001951869,0.0001048202,0.0008939994,0.0002514176,0.00007018005],"category_scores_gemma":[0.0007384782,0.0002384824,0.0003061188,0.0007070518,0.0001873805,0.00008306414,0.0001147959,0.0005543219,0.0000607221],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001149715,"about_ca_system_score_gemma":0.0006794665,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006150574,"about_ca_topic_score_gemma":0.001110381,"domain_scores_codex":[0.9960731,0.001151179,0.001048375,0.0005203038,0.0005241488,0.0006829252],"domain_scores_gemma":[0.9971182,0.0009046534,0.0009318705,0.0006928587,0.000249286,0.000103157],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00009672772,0.0001747205,0.00002822843,0.5676585,0.0001209421,0.00001343738,0.0002008894,3.094734e-7,2.824976e-8,0.000004352552,0.001322935,0.4303789],"study_design_scores_gemma":[0.001026423,0.001477177,0.00001837068,0.7718532,0.002331554,0.00002244567,0.0002050151,0.0000230319,3.443803e-7,0.00002241424,0.2226142,0.0004058283],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006234495,0.9875884,0.00000702055,0.0002764724,0.0001620159,0.01094346,0.0003220817,0.00004561046,0.0005926071],"genre_scores_gemma":[0.0001195727,0.9932411,0.0001390409,0.0002546668,0.0001043372,0.003909311,0.00008021104,0.0001110024,0.002040718],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4299731,"threshold_uncertainty_score":0.9725029,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2155750728","doi":"10.1634/theoncologist.2011-0384","title":"A Prospective Analysis of the Influence of Older Age on Physician and Patient Decision-Making When Considering Enrollment in Breast Cancer Clinical Trials (SWOG S0316)","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Celgene; Eisai; Sanofi; Breast Cancer Research Foundation; Pfizer; GlaxoSmithKline","keywords":"Breast cancer; Medicine; Clinical trial; Oncology; Clinical decision making; Medical decision making; Cancer; Family medicine; Internal medicine; Gerontology","retraction":null,"screen_n_in":null,"score":{"opus":0.3596912363120179,"gpt":0.6029037017443813,"spread":0.2432124654323634,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01330772,0.0001173219,0.0009854937,0.0001122505,0.00006673374,0.000009774027,0.000229978,0.0001883986,0.00004247281],"category_scores_gemma":[0.02886016,0.00005708998,0.0002672044,0.0005267304,0.001186942,0.00004002904,0.0003428287,0.00102075,0.00000136481],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002271048,"about_ca_system_score_gemma":0.000288327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005035134,"about_ca_topic_score_gemma":0.0009974677,"domain_scores_codex":[0.9964072,0.001116056,0.001220825,0.0002547565,0.0007488293,0.0002523547],"domain_scores_gemma":[0.9549515,0.04343774,0.0006734066,0.0005900399,0.0002650797,0.00008226185],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001590565,0.000938703,0.9533067,0.00004871605,0.0006855685,0.000007357109,0.003496698,0.001046468,0.0004646018,0.001238508,0.00008066323,0.03709542],"study_design_scores_gemma":[0.001110537,0.0003146588,0.991415,0.0009598497,0.0005081614,0.000001259903,0.0005522699,0.0001223083,0.0002368427,0.004682239,0.00003960526,0.00005730836],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946138,0.0002137926,0.00001258563,0.003227683,0.0001055633,0.0009398579,0.00002952994,0.000005628852,0.0008515693],"genre_scores_gemma":[0.9974146,0.0002597198,0.0002873353,0.001863298,0.00007769283,0.00006655895,3.340045e-7,0.000008747806,0.00002173898],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04232169,"threshold_uncertainty_score":0.9793202,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2036207363","doi":"10.1634/theoncologist.2009-0275","title":"Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":109,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Hospital for Sick Children; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Tamoxifen; Oncology; Cost effectiveness; Internal medicine; Cost-effectiveness analysis; Quality-adjusted life year; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.07588753672040834,"gpt":0.3807821617072485,"spread":0.3048946249868402,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003637242,0.000191898,0.0003817505,0.00008526201,0.00008820097,0.00001172601,0.0002013158,0.000114734,0.00002088386],"category_scores_gemma":[0.00005143968,0.0001260672,0.0001542937,0.0004935575,0.0003412365,0.000004006753,0.0001008028,0.00008992264,0.000001302323],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002275177,"about_ca_system_score_gemma":0.0001924108,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01301713,"about_ca_topic_score_gemma":0.01464724,"domain_scores_codex":[0.9988967,0.0001994746,0.0002144076,0.0003422612,0.0001085302,0.0002386878],"domain_scores_gemma":[0.9991542,0.00009330473,0.0001656543,0.0004274116,0.0001187526,0.00004072566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004023333,0.0003487419,0.745904,0.000008025271,0.001256878,0.000005390444,0.00018455,0.001611667,0.2400418,0.00002913454,0.00001745738,0.01019008],"study_design_scores_gemma":[0.0009733881,0.0001438589,0.924239,0.00001723315,0.0007383799,0.00001338522,0.00003877586,0.0001739598,0.07333502,0.00001780901,0.0001702421,0.0001389391],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981759,0.0003704133,0.0001173513,0.0001952065,0.0002008053,0.0004324997,0.00031205,0.000007284487,0.0001885206],"genre_scores_gemma":[0.9990893,0.0002242868,0.0001947069,0.00003455001,0.00009552616,0.0002764001,0.000046972,0.00001173227,0.00002651982],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.178335,"threshold_uncertainty_score":0.9935552,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2135743613","doi":"10.1634/theoncologist.12-9-1035","title":"Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity","year":2007,"lang":"en","type":"article","venue":"The Oncologist","topic":"Bone health and treatments","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Juravinski Cancer Centre; University of Waterloo","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Zoledronic acid; Breast cancer; Internal medicine; Bisphosphonate; N-terminal telopeptide; Oncology; Post-hoc analysis; Creatinine; Multiple myeloma; Bone metastasis; Metastatic breast cancer; Hazard ratio; Cancer; Osteoporosis; Urology; Surgery; Confidence interval; Alkaline phosphatase; Osteocalcin","retraction":null,"screen_n_in":null,"score":{"opus":0.01569757500930578,"gpt":0.3016321892029452,"spread":0.2859346141936394,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004007996,0.0001101208,0.0002989582,0.00005221763,0.00005035576,0.000003674761,0.00002509438,0.00004958699,0.00002144282],"category_scores_gemma":[0.00001994099,0.0000614232,0.00001393573,0.0001563588,0.0002751474,0.00004402799,0.00003029122,0.0001317226,7.844372e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001377546,"about_ca_system_score_gemma":0.0001304141,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003994483,"about_ca_topic_score_gemma":0.00866829,"domain_scores_codex":[0.9992411,0.0000696513,0.0001577608,0.0001493732,0.0001438135,0.0002383748],"domain_scores_gemma":[0.9994798,0.000132732,0.0001145342,0.0001202809,0.00004857605,0.0001040957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007693669,0.0004636952,0.9664475,0.0000690619,0.00007186394,0.00003030249,0.00005888809,4.900942e-7,0.0004235584,0.000006149753,0.00002649303,0.02470837],"study_design_scores_gemma":[0.005757681,0.0009317877,0.9921776,0.00006431407,0.0001158819,0.00002597399,0.00009039496,0.000009813898,0.0006956768,0.000004966337,0.00007040455,0.00005550763],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979039,0.0003308285,0.000004143226,0.0009078518,0.00003780204,0.0004448636,0.00008365088,0.00001143245,0.0002755321],"genre_scores_gemma":[0.9996036,0.0001476802,0.0000486982,0.0001024064,0.00000874239,0.00001406598,0.00001121239,0.00000894461,0.00005459222],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02573014,"threshold_uncertainty_score":0.603849,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2156648140","doi":"10.1634/theoncologist.2015-0012","title":"Frequency, Predictors, and Medical Record Documentation of Chemical Coping Among Advanced Cancer Patients","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Pain Management and Opioid Use","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Multinational Association of Supportive Care in Cancer","keywords":"Medicine; Coping (psychology); Medical record; Confidence interval; Odds ratio; Concordance; Palliative care; Psychiatry; Internal medicine; Family medicine; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.02101207527441902,"gpt":0.3204544320849842,"spread":0.2994423568105652,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003439742,0.00007122124,0.0001664884,0.0000242629,0.00002290461,0.00000620258,0.00009234372,0.00006479536,0.00008924685],"category_scores_gemma":[0.0003916628,0.0000454988,0.00002116027,0.00008161212,0.0002813446,0.00007102852,0.00005204218,0.0001106934,0.000002939557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000122179,"about_ca_system_score_gemma":0.00007920287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004064978,"about_ca_topic_score_gemma":0.00008591194,"domain_scores_codex":[0.9991995,0.0000473339,0.0001992793,0.0001199127,0.0003160441,0.0001179917],"domain_scores_gemma":[0.9995005,0.00008563462,0.0001108918,0.0001168845,0.00007312301,0.0001130007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001109989,0.00008010727,0.9847733,0.00004158893,0.00003074403,0.000003877004,0.0003966285,9.520808e-7,0.000312323,0.00007395716,0.005213866,0.008961669],"study_design_scores_gemma":[0.005735606,0.0006868443,0.985566,0.0002972283,0.0001768443,7.533406e-7,0.0003841636,0.0004513946,0.00156028,0.0007199476,0.004283239,0.0001376615],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953521,0.0002249488,0.00004681288,0.001393713,0.0002268194,0.0003468342,0.000002920919,0.00002929757,0.00237656],"genre_scores_gemma":[0.9984121,0.000322716,0.0004282595,0.0004499028,0.0001072735,0.00003960629,0.00002639904,0.000006644253,0.0002070705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008824008,"threshold_uncertainty_score":0.1855387,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2950856878","doi":"10.1634/theoncologist.2019-0019","title":"Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":95,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of Calgary; University of Alberta","funders":"Genentech; Pfizer","keywords":"Letrozole; Palbociclib; Medicine; Oncology; Internal medicine; Postmenopausal women; Randomized controlled trial; Breast cancer; Cancer; Gynecology; Tamoxifen; Metastatic breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.006386544342530553,"gpt":0.2729757012801935,"spread":0.2665891569376629,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009739283,0.0003407684,0.002030791,0.0001600523,0.0001025222,0.00001311234,0.0004290497,0.0001137351,0.0006128011],"category_scores_gemma":[0.00007351371,0.0001400992,0.0001880457,0.001681742,0.001085396,0.0001005537,0.00009426703,0.0004103775,0.000006666522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007656435,"about_ca_system_score_gemma":0.0004577709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007122763,"about_ca_topic_score_gemma":0.001425655,"domain_scores_codex":[0.9973913,0.0004888927,0.0006335208,0.0004375234,0.0005136718,0.0005350605],"domain_scores_gemma":[0.9975091,0.0006617699,0.0006786918,0.0009057162,0.0001584155,0.0000862832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.948518,0.0003858662,0.03558128,0.00005046358,0.002402587,0.00002202407,0.001073222,0.005502708,0.001111121,0.0003483636,0.000006766729,0.004997637],"study_design_scores_gemma":[0.8193256,0.003196773,0.1693054,0.0002681282,0.002350341,0.0001465815,0.003201554,0.000378333,0.0003898745,0.0002337326,0.0008287422,0.0003749496],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9897326,0.0004929054,0.00008447516,0.004695114,0.0001468969,0.003255115,0.00009032962,0.0000592807,0.00144334],"genre_scores_gemma":[0.9973052,0.000121712,0.0003246208,0.0007680294,0.00006583508,0.0006696353,0.00001438093,0.00003596873,0.00069464],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1337241,"threshold_uncertainty_score":0.6709743,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2126451936","doi":"10.1634/theoncologist.2011-0458","title":"Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors","year":2012,"lang":"en","type":"review","venue":"The Oncologist","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Pfizer","keywords":"Medicine; Somatostatin; Neuroendocrine tumors; Cancer research; Somatostatin receptor; Pharmacology; Internal medicine; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.06464550285194756,"gpt":0.4085036108327406,"spread":0.3438581079807931,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003438962,0.0005304922,0.0029759,0.0004668905,0.00005838355,0.0000153724,0.0006739275,0.00002153001,0.00007356847],"category_scores_gemma":[0.001631084,0.0003038289,0.0004545923,0.0009949121,0.0007169964,0.00008697944,0.0003932859,0.001249721,0.0001510174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002241823,"about_ca_system_score_gemma":0.0005679892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001648784,"about_ca_topic_score_gemma":0.00007423188,"domain_scores_codex":[0.9961808,0.0008585211,0.001028392,0.0004618758,0.000546283,0.0009241591],"domain_scores_gemma":[0.9959137,0.002189585,0.0006545175,0.0009556282,0.0000643416,0.0002221755],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000171426,0.001324696,0.001391216,0.1254439,0.0001801124,0.04512895,0.00003631578,0.000001391868,0.00004989133,0.0006182308,0.001561514,0.8240924],"study_design_scores_gemma":[0.001238576,0.001287903,0.0009436383,0.01098831,0.0008716646,0.01004157,0.00002603451,0.000002262221,0.0002210059,0.00006292218,0.9740223,0.0002937978],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002075125,0.9921477,0.000001288728,0.000280982,0.000300798,0.003164704,0.00002562512,0.00007233118,0.001931483],"genre_scores_gemma":[0.005529812,0.9925035,0.0001327659,0.0001127852,0.0001916193,0.000360669,0.0000457205,0.00009496365,0.001028226],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9724608,"threshold_uncertainty_score":0.9999414,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2108757112","doi":"10.1634/theoncologist.2014-0438","title":"Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Nausea and vomiting management","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Antiemetic; Medicine; Nausea; Chemotherapy-induced nausea and vomiting; Vomiting; Intensive care medicine; Chemotherapy; Quality of life (healthcare); Anesthesia; Internal medicine; Nursing","retraction":null,"screen_n_in":null,"score":{"opus":0.09718358085502046,"gpt":0.3713657553445975,"spread":0.274182174489577,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008711724,0.0001686475,0.0003017044,0.00005921642,0.0001392394,0.00003832971,0.0001484206,0.00009399268,0.00003113661],"category_scores_gemma":[0.0004337698,0.000105827,0.00007254148,0.0001142818,0.000161635,0.00003204561,0.00006364697,0.0001433607,0.00008422333],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001577938,"about_ca_system_score_gemma":0.00008593902,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003358585,"about_ca_topic_score_gemma":0.00000517131,"domain_scores_codex":[0.9989681,0.00004943012,0.0001951959,0.0002682192,0.0002270509,0.0002920043],"domain_scores_gemma":[0.9989881,0.0002886679,0.0001027406,0.000370374,0.00009287282,0.0001572284],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01336047,0.00277368,0.01849265,0.0005263455,0.001467791,0.0002502712,0.005695032,0.00003395741,0.03132046,0.009277328,0.6557427,0.2610593],"study_design_scores_gemma":[0.05186609,0.01818167,0.09350277,0.0004750307,0.00126248,0.0001947187,0.003485742,0.004314478,0.0376932,0.004640547,0.7830551,0.001328194],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9391181,0.00007883235,0.00005435399,0.03229797,0.0001402884,0.001170732,0.000007264041,0.0001586647,0.02697382],"genre_scores_gemma":[0.9835105,0.00002214318,0.0007782187,0.006286387,0.0005082507,0.00009553844,0.00001449287,0.00003711066,0.008747347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2597311,"threshold_uncertainty_score":0.4315499,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125128981","doi":"10.1634/theoncologist.7-suppl_1-14","title":"Molecular Targets of Arsenic Trioxide in Malignant Cells","year":2002,"lang":"en","type":"review","venue":"The Oncologist","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":92,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Arsenic trioxide; Acute promyelocytic leukemia; Medicine; Cancer research; Apoptosis; Signal transduction; Intracellular; Leukemia; Cell biology; Immunology; Chemistry; Biology; Biochemistry; Cell culture; Retinoic acid; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.03006219893206586,"gpt":0.3076100935999599,"spread":0.2775478946678941,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000496515,0.0003849478,0.001055768,0.00007439469,0.00003916341,0.00001442682,0.000882281,0.0005925475,0.00003954986],"category_scores_gemma":[0.0001350337,0.0002455379,0.0004854749,0.0002473792,0.0003360137,0.00000150068,0.0002476394,0.0003419161,0.00003920129],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008906928,"about_ca_system_score_gemma":0.0004096861,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002636181,"about_ca_topic_score_gemma":0.00001921574,"domain_scores_codex":[0.9979127,0.0003738558,0.0007097985,0.0004748483,0.0001744359,0.0003543397],"domain_scores_gemma":[0.9985384,0.0000706684,0.0005167687,0.0007753586,0.00004923472,0.00004950529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007752347,0.0006915429,0.00002365244,0.01577673,0.0005736591,0.0004883246,0.00007925192,0.0001936469,0.05054236,0.0004563968,0.009105516,0.9219914],"study_design_scores_gemma":[0.0002372657,0.0002195688,5.447886e-7,0.0009579876,0.0002189069,0.00003512148,0.00002353493,0.00000356122,0.02920564,0.00004503878,0.9687569,0.0002959157],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009378479,0.9939234,0.00008348929,0.000020605,0.0001981636,0.0005759331,0.00002273446,0.000008467001,0.004229411],"genre_scores_gemma":[0.002687112,0.9952077,0.000172813,0.00005670609,0.0001265887,0.0001077268,0.00008932934,0.00005125503,0.001500737],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9596514,"threshold_uncertainty_score":0.9999997,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2095839943","doi":"10.1634/theoncologist.2009-0298","title":"Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms","year":2010,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Chemoradiotherapy; Stage (stratigraphy); Oncology; Current (fluid); Lung cancer; Internal medicine; Cancer; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1446174652254063,"gpt":0.4771418083636698,"spread":0.3325243431382635,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004812404,0.0008049084,0.003060082,0.0001490854,0.0002967784,0.0000666335,0.0006713819,0.0003867421,0.0003372088],"category_scores_gemma":[0.00008105391,0.00039418,0.0008650989,0.0004049182,0.0006401873,0.00002580726,0.0001701487,0.00154675,0.00009808387],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00424088,"about_ca_system_score_gemma":0.002921937,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007396706,"about_ca_topic_score_gemma":0.0005618329,"domain_scores_codex":[0.9971324,0.0002724756,0.0006215947,0.0007166481,0.0004378122,0.0008191082],"domain_scores_gemma":[0.9971616,0.0006149225,0.0005129437,0.001332679,0.0001041442,0.0002737207],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005761911,0.0004790577,0.0001586623,0.01373028,0.0006233564,0.00009389944,0.0002202671,8.448955e-7,0.000002735458,0.00004497292,0.01171208,0.9728763],"study_design_scores_gemma":[0.001363732,0.0006495574,0.00002832804,0.004113937,0.002741555,0.00003485363,0.00002054094,0.00001664339,0.00001657425,0.000003196079,0.9906451,0.0003660548],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005373179,0.9831479,0.000006941882,0.001199862,0.00124672,0.00499349,0.0002502806,0.0001597141,0.008941378],"genre_scores_gemma":[0.000006687213,0.9726223,0.0001045243,0.0001377343,0.002009457,0.003428889,0.0001206214,0.0001211188,0.02144867],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.978933,"threshold_uncertainty_score":0.999851,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133017309","doi":"10.1634/theoncologist.6-3-257","title":"Review of Recent Advances in Fluorescence Bronchoscopy in Early Localization of Central Airway Lung Cancer","year":2001,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Field cancerization; Lung cancer; Bronchoscopy; Malignancy; Radiology; Autofluorescence; Sputum; Occult; Lung; Cancer; Airway obstruction; Pathology; Airway; Surgery; Internal medicine; Tuberculosis","retraction":null,"screen_n_in":null,"score":{"opus":0.0421778709408694,"gpt":0.4129237320005013,"spread":0.3707458610596319,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003925402,0.0002617162,0.001917767,0.00009987954,0.00001621406,0.000003206898,0.0002177824,0.0001478145,0.0002680125],"category_scores_gemma":[0.000134176,0.0001493356,0.0002014817,0.0008827972,0.0001840229,0.00005202251,0.00004623571,0.0002611154,0.00000275214],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001950937,"about_ca_system_score_gemma":0.0008448464,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001303403,"about_ca_topic_score_gemma":0.001292882,"domain_scores_codex":[0.997942,0.0002529485,0.0009775299,0.0002985065,0.0002469195,0.0002821409],"domain_scores_gemma":[0.9985687,0.0001815163,0.000697132,0.0004023381,0.00009604805,0.00005427963],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00003984229,0.0003754735,0.01116377,0.1251419,0.00005848128,0.00001890224,0.00005885643,0.00002137633,5.644223e-8,0.00002839724,0.001423796,0.8616692],"study_design_scores_gemma":[0.0004810785,0.0002157356,0.0006359033,0.3056661,0.0007187608,0.000004164231,0.000005841947,0.000009015625,0.000006025951,0.000004040846,0.692162,0.0000913624],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00001116755,0.9957066,0.00001250645,0.0004279304,0.0002433955,0.002389803,0.00003586665,0.00000817798,0.001164579],"genre_scores_gemma":[0.00006177153,0.9989454,0.00005757467,0.0001937988,0.00008065059,0.0005304012,0.00005903725,0.000021978,0.00004943681],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8615778,"threshold_uncertainty_score":0.6089728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2110202780","doi":"10.1634/theoncologist.2015-0058","title":"Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer","year":2015,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Body mass index; Lean body mass; Toxicity; Body surface area; Afatinib; Lung cancer; Body surface; Internal medicine; Cancer; Oncology; Gastroenterology; Body weight; Gefitinib","retraction":null,"screen_n_in":null,"score":{"opus":0.01356719596799208,"gpt":0.2927484974397723,"spread":0.2791813014717802,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001717016,0.0002088956,0.0002827856,0.00006567929,0.0001217606,0.00003322186,0.00006057414,0.00008558928,0.00002950716],"category_scores_gemma":[0.0000453335,0.0001443381,0.00001914682,0.000238787,0.0001239607,0.0001033953,0.00003838032,0.000299583,0.0000021967],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007852288,"about_ca_system_score_gemma":0.0004259578,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001170677,"about_ca_topic_score_gemma":0.0002395876,"domain_scores_codex":[0.9987655,0.00006840195,0.0002492982,0.0003461445,0.0002517601,0.0003188637],"domain_scores_gemma":[0.9991223,0.00005345519,0.0001736473,0.0001731945,0.0002111927,0.0002661859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001458008,0.0006493392,0.9884712,0.0000650006,0.00006197859,0.00002198642,0.0004465843,0.0003007091,0.005518912,0.000007489024,0.002870218,0.0001285602],"study_design_scores_gemma":[0.01247213,0.002097042,0.9823346,0.0003519333,0.0001826834,0.00002919769,0.001173708,0.0005188851,0.0004736864,0.00006698548,0.0001006841,0.0001985242],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960229,0.0001221797,0.00003789964,0.0012199,0.00009246683,0.001386177,0.0002062054,0.0000343314,0.0008779536],"genre_scores_gemma":[0.9976597,0.00002826827,0.001049491,0.0001519387,0.00003958914,0.00009579401,0.0002209091,0.00002411506,0.000730133],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01101412,"threshold_uncertainty_score":0.5885938,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2968495081","doi":"10.1634/theoncologist.2019-0297","title":"Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with<i>RAS/RAF</i>Alterations","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; National Center for Advancing Translational Sciences; Array BioPharma","keywords":"KRAS; Medicine; Neuroblastoma RAS viral oncogene homolog; MEK inhibitor; Internal medicine; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Toxicity; Phases of clinical research; Pharmacology; Colorectal cancer; MAPK/ERK pathway; Kinase","retraction":null,"screen_n_in":null,"score":{"opus":0.009872657720289805,"gpt":0.3163407426654571,"spread":0.3064680849451673,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001402453,0.0002264155,0.0004390922,0.0001128471,0.0001346135,0.00003116457,0.0000786938,0.00004226327,0.00002599958],"category_scores_gemma":[0.00001958289,0.0001167363,0.00001970056,0.0004135782,0.0001877318,0.0002029881,0.00002254287,0.0001607271,0.000002463069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000147331,"about_ca_system_score_gemma":0.0002318863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001856575,"about_ca_topic_score_gemma":0.0002852364,"domain_scores_codex":[0.9986803,0.0000946685,0.0003451528,0.0003243489,0.0003517685,0.0002037649],"domain_scores_gemma":[0.9988884,0.0001336494,0.0002902049,0.0003353069,0.0002743226,0.00007815511],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01631273,0.02899815,0.9314007,0.00006812712,0.0004056098,0.00003829009,0.008857426,0.0003489198,0.001186126,0.0001395045,0.0001100164,0.01213441],"study_design_scores_gemma":[0.1621848,0.113033,0.7066556,0.0004529758,0.0004194385,0.00001026682,0.005863289,0.0001348284,0.01059737,0.00001837958,0.0002926727,0.0003373381],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946492,0.0001113485,0.0000153329,0.0003672733,0.00007727388,0.004304452,0.00003705981,0.00003467387,0.0004034358],"genre_scores_gemma":[0.9987894,0.00001942171,0.0003474029,0.0001549097,0.00002990068,0.0003284491,0.0001130812,0.00003018751,0.0001872347],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2247451,"threshold_uncertainty_score":0.4760368,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105446438","doi":"10.1634/theoncologist.2013-0249","title":"Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Stage (stratigraphy); Lymphoma; Internal medicine; Radiation therapy; Confidence interval; Diffuse large B-cell lymphoma; Chemotherapy; Gastroenterology; International Prognostic Index; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.01654700549942697,"gpt":0.288071779150658,"spread":0.2715247736512311,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005235936,0.0001315682,0.000342678,0.00003211088,0.00008412332,0.00001159098,0.0002715249,0.00005303019,0.00001031263],"category_scores_gemma":[0.00009009116,0.0000522391,0.00008498225,0.0001174874,0.0004784639,0.00005093547,0.0002258817,0.00006445269,8.574644e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004225726,"about_ca_system_score_gemma":0.00003026861,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001128612,"about_ca_topic_score_gemma":0.0002504637,"domain_scores_codex":[0.9987165,0.0002318112,0.0003771868,0.0001949334,0.0003518323,0.000127781],"domain_scores_gemma":[0.9986368,0.0002399643,0.0004186509,0.0005361802,0.0001268749,0.000041491],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0009569748,0.02595722,0.9616462,0.00005617509,0.0003511032,0.000005887521,0.0004448465,0.000001074889,0.000006272476,0.0008366976,0.0004641807,0.009273388],"study_design_scores_gemma":[0.01776748,0.00368607,0.9713962,0.00006077521,0.0004647287,0.000003243426,0.0007621249,0.00002022879,0.0004660173,0.00002161506,0.005297964,0.00005355335],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994077,0.00007135316,0.000002012505,0.0006483857,0.000111562,0.001130719,0.00005164517,0.00001065095,0.003896691],"genre_scores_gemma":[0.9983332,0.0001259917,0.0001931851,0.0002202948,0.0000348218,0.00007263545,0.00001895814,0.00001113038,0.0009897427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02227115,"threshold_uncertainty_score":0.2130249,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3113051965","doi":"10.1002/onco.13625","title":"Timing of Palliative Care Referral Before and After Evidence from Trials Supporting Early Palliative Care","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Kelowna General Hospital; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of Toronto","keywords":"Palliative care; Referral; Medicine; Nursing; Intensive care medicine; Family medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.4021487820694182,"gpt":0.4974772671245456,"spread":0.09532848505512737,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003828014,0.0002128001,0.0009957792,0.00003351647,0.00006789378,0.00001448063,0.0001786603,0.0001389554,0.0001290784],"category_scores_gemma":[0.004527678,0.0001316954,0.000185945,0.000172388,0.0003794114,0.00008568611,0.0001483389,0.0002778062,0.000008208555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001374035,"about_ca_system_score_gemma":0.0001614669,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001143748,"about_ca_topic_score_gemma":0.000464264,"domain_scores_codex":[0.9981184,0.0003017869,0.0006998238,0.0003264898,0.0003182054,0.0002353096],"domain_scores_gemma":[0.997105,0.001461159,0.0006525185,0.000242124,0.0004117094,0.0001275123],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001428837,0.00001637806,0.7533699,0.0003776865,0.0001929565,0.00005490129,0.2353436,0.000004792732,0.002062258,0.00001945848,0.0001818798,0.006947279],"study_design_scores_gemma":[0.001933335,0.002611082,0.8540065,0.003346469,0.000805728,3.351917e-7,0.1118785,0.00006885784,0.02398619,0.0001416913,0.001014017,0.0002073117],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833655,0.01247708,0.0001231717,0.002269721,0.00009012714,0.0006216294,0.0002316282,0.00003347103,0.0007877021],"genre_scores_gemma":[0.9953198,0.0006045546,0.0030875,0.0004954492,0.000336183,0.00004475398,0.00004977413,0.0000189499,0.0000430193],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1234651,"threshold_uncertainty_score":0.5420381,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2759254671","doi":"10.1634/theoncologist.2017-0205","title":"Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK)","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sanofi","keywords":"Medicine; Pulmonary embolism; Lung cancer; Internal medicine; Thrombosis; Deep vein; Cancer; Prospective cohort study; Venous thrombosis; Proportional hazards model; Population; Cohort study; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.03100602823453694,"gpt":0.355612829883407,"spread":0.32460680164887,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006606799,0.0001827492,0.0008650654,0.00003025784,0.0002674914,0.00005605254,0.0003568075,0.0000855531,0.00001560771],"category_scores_gemma":[0.0002781292,0.000123169,0.00005976439,0.0000870833,0.0005156067,0.00009405438,0.0003506347,0.0002104326,0.000001655283],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003736134,"about_ca_system_score_gemma":0.0001672309,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.2836358,"about_ca_topic_score_gemma":0.06158033,"domain_scores_codex":[0.9984607,0.0001006776,0.0004343048,0.0004188386,0.0003146501,0.0002708966],"domain_scores_gemma":[0.9984203,0.00008720832,0.0004218812,0.0009167026,0.00007256566,0.00008133184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004149567,0.00246687,0.9886906,0.00003090528,0.0006501182,0.00008758536,0.005449755,0.00001366893,0.00002381172,0.0003645783,0.0005419732,0.001265137],"study_design_scores_gemma":[0.004343794,0.001337967,0.9910167,0.0001226467,0.0008767058,0.000001333918,0.001311835,0.00004393196,0.00004694899,0.0007085299,0.00007744324,0.0001121384],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877183,0.0005064068,0.000001861839,0.000945034,0.0004244271,0.002284611,0.0002406537,0.00003339996,0.00784532],"genre_scores_gemma":[0.9989761,0.0004942543,0.0000267083,0.00007755135,0.000202949,0.0001644012,0.000005852694,0.00001162304,0.0000405734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2220555,"threshold_uncertainty_score":0.9555434,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4255053766","doi":"10.1634/theoncologist.5-6-510","title":"The Cell Cycle","year":2000,"lang":"en","type":"article","venue":"The Oncologist","topic":"","field":"","cited_by":84,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01279018563905355,"gpt":0.2703579673170322,"spread":0.2575677816779786,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008880052,0.000101104,0.00009176731,0.000008186626,0.000704677,0.00007819114,0.0007450394,0.00004635756,0.001673511],"category_scores_gemma":[0.00005214857,0.00004445457,0.00006009007,0.0001889835,0.0006735321,0.00004069787,0.0000586551,0.0001992945,0.0658438],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000133737,"about_ca_system_score_gemma":0.00005453848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002433837,"about_ca_topic_score_gemma":0.0003671258,"domain_scores_codex":[0.9989578,0.0002383751,0.000141064,0.0001384827,0.0001823653,0.0003419454],"domain_scores_gemma":[0.9987875,0.0004544225,0.00005948915,0.0006354988,0.00002059036,0.00004249424],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005112333,0.0004544634,0.0006562426,0.000004519662,0.00004110528,0.00004235301,0.00111384,0.002541889,0.006403575,0.004380925,0.828616,0.1552338],"study_design_scores_gemma":[0.0003448523,0.0001015079,0.00581947,0.000001678457,0.00002002931,0.00001017901,0.0002186983,0.0003808203,0.001570369,0.003011002,0.9884235,0.0000978758],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.4117053,0.0003079712,0.000001340662,0.003018536,0.0001025799,0.0001853209,0.00001074825,0.0001729699,0.5844952],"genre_scores_gemma":[0.9493615,0.00009442,0.00005169812,0.0005650626,0.0001776284,0.00003464078,0.000002093909,0.00003269205,0.04968026],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.5376562,"threshold_uncertainty_score":0.9992391,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1973742157","doi":"10.1634/theoncologist.2013-0359","title":"Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects","year":2014,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Ottawa Hospital; Royal Victoria Hospital; Ottawa Regional Cancer Foundation; University of Ottawa","funders":"","keywords":"Medicine; Conjoint analysis; Breast cancer; Oncology; Chemotherapy; Internal medicine; Cancer; Preference; Statistics","retraction":null,"screen_n_in":null,"score":{"opus":0.0910081580114505,"gpt":0.3948186789986069,"spread":0.3038105209871564,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001540539,0.0001095573,0.0004163763,0.0000674519,0.00004784053,0.000009563842,0.00007790407,0.00004890618,0.0001271067],"category_scores_gemma":[0.00005224493,0.00006151853,0.0001431659,0.0002352308,0.0001043507,0.0000219873,0.00002283602,0.0000550556,0.000003280652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001327529,"about_ca_system_score_gemma":0.00008319748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001561277,"about_ca_topic_score_gemma":0.001247256,"domain_scores_codex":[0.9992977,0.00008980313,0.0001752352,0.0001684783,0.0001062453,0.0001624998],"domain_scores_gemma":[0.9987323,0.0007516299,0.0001265418,0.0001993801,0.0001177014,0.00007248046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.009106521,0.002088216,0.2365111,0.0003234262,0.007849892,0.000007592471,0.002064057,0.002190837,0.0756422,0.0004705304,0.02294857,0.6407971],"study_design_scores_gemma":[0.004147923,0.005700015,0.8547455,0.0000701469,0.005419485,0.000007875396,0.00008996316,0.001288424,0.08078411,0.0001847094,0.04734866,0.0002131849],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919852,0.00007769598,0.0006550067,0.005304767,0.000178596,0.001035107,0.00007327474,0.00002336528,0.0006669657],"genre_scores_gemma":[0.9953775,0.0000777648,0.0005936066,0.003040009,0.0001275158,0.0004186785,0.00001641015,0.000007523106,0.000340962],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6405839,"threshold_uncertainty_score":0.2508653,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}